Free Trial
LON:INS

Instem (INS) Share Price, News & Analysis

Instem logo
GBX 830 0.00 (0.00%)
(As of 11/20/2023)

About Instem Stock (LON:INS)

Key Stats

Today's Range
830
830
50-Day Range
830
830
52-Week Range
580
835.56
Volume
3,800 shs
Average Volume
85,542 shs
Market Capitalization
£199.62 million
P/E Ratio
5,928.57
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

Receive INS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter.

INS Stock News Headlines

What do “they” know that you don’t?
Over the past decade, the Central Bank trade has been clear: Sell Treasuries, buy gold. In fact, Central Banks have now DOUBLED their gold stake - sending stockpiles to the highest level since the '90s, according to The Kobeissi Letter.
The Best Gravel Bike Shoes of 2024
The Wrap: Maternal healthcare
See More Headlines

INS Stock Analysis - Frequently Asked Questions

Instem's stock was trading at GBX 830 at the beginning of the year. Since then, INS stock has increased by 0.0% and is now trading at GBX 830.
View the best growth stocks for 2024 here
.

Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Instem investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX).

Industry, Sector and Symbol

Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
500
Year Founded
N/A

Profitability

Net Income
£3.34 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£61.63 million
Cash Flow
GBX 54.41 per share
Book Value
GBX 239 per share

Miscellaneous

Free Float
N/A
Market Cap
£199.62 million
Optionable
Not Optionable
Beta
0.42
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (LON:INS) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners